SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Adv Drug Deliv Rev
; 172: 314-338, 2021 05.
Article
in English
| MEDLINE | ID: covidwho-1039241
ABSTRACT
The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Clinical Trials, Phase III as Topic
/
COVID-19 Vaccines
/
SARS-CoV-2
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Traditional medicine
/
Vaccines
Limits:
Animals
/
Humans
Language:
English
Journal:
Adv Drug Deliv Rev
Journal subject:
Pharmacology
/
Drug Therapy
Year:
2021
Document Type:
Article
Affiliation country:
J.addr.2021.01.014
Similar
MEDLINE
...
LILACS
LIS